Tests HBI0101 CAR-T cell therapy in adults with relapsed multiple myeloma

Trial details

Who runs it

Hadassah Medical Organization

Trial code

NCT07333430

Record updated

16 October 2026

Original description

A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.Read full original descriptionShow less

A Phase 1a/1b Open-Label Study With Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.

Inclusion: ≥18 years of age at the time of signing informed consent; Voluntarily signed informed consent form; Diagnosis of relapsed/refractory multiple myeloma (Parts 1a and 1b), with measurable disease at screening visit as follows:; Multiple Myeloma (at least one of the criteria below):; Serum M-protein greater or equal to 0.5 g/dL; Urine M-protein greater or equal to 200 mg/24 h; Serum free light chain (FLC) assay: involved FLC level greater or equal to 3 mg/dL (30 mg/L) provided serum FLC ratio is abnormal; A biopsy-proven evaluable plasmacytoma*; Bone marrow plasma cells > 10% of total bone marrow cells*; Non secretory patient will be allowed provided they have measurable disease by PET-CT or bone marrow aspiration, as designated*; Results pre-dating the Screening visit by up to 28 days may be used to establish eligibility; R/R MM subjects must have been exposed to at least three prior lines of therapy including the following agents:; proteasome inhibitor; immunomodulatory (IMiDs) agent; anti-CD38 antibody; For part 1a: At least one of the following risk factors: a. Extra-medullary disease (EMD) - defined as a MM lesion that is not connected to a bone. b. previous exposure to an anti-BCMA therapy; Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2; Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study; Recovery to ≤ Grade 2 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy, and toxicities that are irreversible and not expected to interfere with study treatment or pose safety concerns, per investigator judgement; Ability and willingness to adhere to the study visit schedule and all protocol requirements; For subjects with relapsed multiple myeloma who have previously undergone allogenic stem cell transplantation: no evidence of graft versus host disease after cessation of any immunosuppressive therapy for at least one month before recruitment to the study.

Exclusion: Ongoing treatment with chronic immunosuppressant such as cyclosporine or systemic steroids (physiological replacement doses of steroids are allowed up to 12 mg/m2/d hydrocortisone or equivalent); Known bulky central nervous system disease; Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions; Known human immunodeficiency virus (HIV) positive status; Active Hepatitis B active infection (defined as HBS-antigen and HBV DNA positive) or Hepatitis C active infection (defined as anti-HCV and HCV RNA positive); Active CMV infection; Known history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months; Chronic atrial fibrillation with uncontrolled heart rate; Second primary malignancy that has required therapy in the last 2 years or is not in complete remission. This exclusion criterion does not exclude the following subjects: successfully treated non- metastatic basal cell or squamous cell skin carcinoma, or prostate cancer under control with hormonal therapy; Subjects who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:; Have been on a stable dose of anticoagulation for < 1 month (except for acute line insertion induced thrombosis; Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days; Are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement); Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) and/or direct bilirubin > 4x ULN; Inadequate renal function defined by estimated clearance of <20(ml/min); International ratio (INR) or partial thromboplastin time (PTT) > 2 x ULN, unless on a stable dose of anticoagulant for a thromboembolic event (provided this event is not an exclusion criteria); Inadequate bone marrow function defined by absolute neutrophil count (ANC) < 1000 cells/mm3, platelet count < 30,000 mm3, or hemoglobin < 8 g/dL. Subjects with absolute lymphocyte count < 300 cells/mm3 may be excluded (due to potential challenges with producing CART), per investigator judgement; Left ventricular ejection fraction < 40%; Contraindication to a study treatment/procedure or is anticipated to receive treatment/procedure that may preclude performance of study procedures; Pregnant or lactating women.

ClinicalTrials.gov NCT07333430